The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10428 malaria professionals are enjoying the free benefits of MalariaWorld today

malaria treatment

NOT Open Access | Ethnopharmacology-aided antiplasmodial evaluation of six selected plants used for malaria treatment in Nigeria

March 2, 2020 - 14:39 -- NOT Open Access
Author(s): 
Ezenyi IC, Verma V, Singh S, Okhale SE, Adzu B
Reference: 
J Ethnopharmacol. 2020 Feb 21:112694

Sub – Saharan Africa has a high malaria burden and Nigeria accounts for majority of malaria cases worldwide. The aim of this study was to evaluate selected plants extracts used against malaria in Nigeria for antiplasmodial activity.

Usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with artemether-lumefantrine in Tanzania

February 14, 2020 - 16:51 -- Open Access
Author(s): 
Manase Kilonzi, Omary Minzi, Ritah Mutagonda, Vito Baraka, Philip Sasi, Eleni Aklillu and Appolinary Kamuhabwa
Reference: 
Malaria Journal 2020 19:66, 11 February 2020

Day 7 plasma lumefantrine concentration is suggested as a predictor for malaria treatment outcomes and a cut-off of ≥ 200 ng/ml is associated with day 28 cure rate in the general population. However, day 7 lumefantrine plasma concentration can be affected by age, the extent of fever, baseline parasitaemia, and bodyweight. Therefore, this study assessed the usefulness of day 7 lumefantrine plasma concentration as a predictor of malaria treatment outcome in under-fives children treated with generic or innovator drug-containing artemether-lumefantrine (ALu) in Tanzania.

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

October 8, 2019 - 14:57 -- Open Access
Author(s): 
Eugenia Lo, Daibin Zhong, Beka Raya, Kareen Pestana, Cristian Koepfli, Ming-Chieh Lee, Delenasaw Yewhalaw and Guiyun Yan
Reference: 
Malaria Journal 2019 18:340, 7 October 2019

G6PD enzyme deficiency is a common enzymatic X-linked disorder. Deficiency of the G6PD enzyme can cause free radical-mediated oxidative damage to red blood cells, leading to premature haemolysis. Treatment of Plasmodium vivax malaria with primaquine poses a potential risk of mild to severe acute haemolytic anaemia in G6PD deficient people. In this study, the prevalence and distribution of G6PD mutations were investigated across broad areas of Ethiopia, and tested the association between G6PD genotype and phenotype with the goal to provide additional information relevant to the use of primaquine in malaria treatment.

Country: 
Subscribe to RSS - malaria treatment